Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2020-04-13 Purchase | 2023-01-20 4:32 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 1,191 | $20.98 | $24,987 | 575,492 (Indirect Direct) | View |
2022-07-15 Sale | 2022-07-19 4:40 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 46,034 | $30 | $1,381,020 | 103,855 (Direct) | View |
2022-07-13 Sale | 2022-07-15 4:40 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 1,916 | $30 | $57,480 | 149,889 (Direct) | View |
2022-05-11 Sale | 2022-05-13 4:37 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $41.9 | $222,050 | 151,805 (Direct) | View |
2022-04-11 Sale | 2022-04-13 4:36 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $62.77 | $332,705 | 157,105 (Direct) | View |
2022-04-06 Sale | 2022-04-08 4:21 pm | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 1,728 | $65 | $112,320 | 8,002 (Direct) | View |
2022-04-04 Sale | 2022-04-06 4:49 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 7,950 | $60 | $477,000 | 162,405 (Direct) | View |
2022-04-01 Sale | 2022-04-05 4:31 pm | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 864 | $57.49 | $49,675 | 9,730 (Direct) | View |
2022-03-11 Sale | 2022-03-15 4:37 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $53.38 | $141,449 | 170,355 (Direct) | View |
2022-02-11 Sale | 2022-02-15 4:26 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $52.06 | $137,965 | 173,005 (Direct) | View |
2022-01-11 Sale | 2022-01-13 4:39 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $53.75 | $142,447 | 175,655 (Direct) | View |
2022-01-05 Sale | 2022-01-07 4:35 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $60 | $159,000 | 178,305 (Direct) | View |
2022-01-03 Sale | 2022-01-05 7:14 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 47,651 | $57.84 | $2,756,116 | 232,727 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2023-05-01 Option Award | 2023-05-03 4:45 pm | N/A 2033-04-30 | Keros Therapeutics Inc. | KROS | Seth Alpna Director | 20,000 | $0 | 20,000 (Direct) | View |
2023-04-08 Exercise | 2023-04-11 4:05 pm | N/A 2029-06-18 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 4,000 | $0 | 297,943 (Direct) | View |
2023-04-08 Exercise | 2023-04-11 4:05 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 4,000 | $0.48 | 297,943 (Direct) | View |
2023-02-16 Option Award | 2023-02-17 4:19 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 100,000 | $0 | 100,000 (Direct) | View |
2023-02-16 Option Award | 2023-02-17 4:15 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Cooper Simon Peter Chief Medical Officer | 40,000 | $0 | 40,000 (Direct) | View |
2023-02-16 Option Award | 2023-02-17 4:14 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $0 | 40,000 (Direct) | View |
2023-02-16 Option Award | 2023-02-17 4:13 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 200,000 | $0 | 200,000 (Direct) | View |
2022-11-29 Exercise | 2022-11-30 4:42 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
2022-11-29 Exercise | 2022-11-30 4:42 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
2022-11-29 Exercise | 2022-11-30 4:38 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
2022-11-29 Exercise | 2022-11-30 4:38 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
Ownership(A) | 2022-11-30 4:37 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 0 | $0 | 7,176 (Indirect) | View |
Ownership(A) | 2022-11-30 4:36 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 0 | $0 | 7,176 (Indirect) | View |
Ownership(A) | 2022-11-30 4:34 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 0 | $0 | 7,176 (Indirect) | View |
2022-07-15 Exercise | 2022-07-19 4:40 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 46,034 | $0 | 103,855 (Direct) | View |
2022-07-15 Exercise | 2022-07-19 4:40 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 46,034 | $0.3 | 103,855 (Direct) | View |
2022-07-13 Exercise | 2022-07-15 4:40 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 1,916 | $0 | 149,889 (Direct) | View |
2022-07-13 Exercise | 2022-07-15 4:40 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 1,916 | $0.3 | 149,889 (Direct) | View |
2022-06-14 Exercise | 2022-06-14 6:57 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 9,400 | $0 | 151,805 (Direct) | View |
2022-06-14 Exercise | 2022-06-14 6:57 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 9,400 | $0.3 | 151,805 (Direct) | View |
2022-06-09 Exercise | 2022-06-10 4:12 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 5,000 | $0 | 257,678 (Direct) | View |
2022-06-09 Exercise | 2022-06-10 4:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 5,000 | $0.3 | 257,678 (Direct) | View |
2022-06-01 Option Award | 2022-06-03 4:30 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 8,293 | $0 | 8,293 (Direct) | View |
2022-06-01 Option Award | 2022-06-03 4:28 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 8,293 | $0 | 8,293 (Direct) | View |
2022-06-01 Option Award | 2022-06-03 4:27 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 8,293 | $0 | 8,293 (Direct) | View |
2022-06-01 Option Award | 2022-06-03 4:26 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | GRAY MARY ANN Director | 8,293 | $0 | 8,293 (Direct) | View |
2022-06-01 Option Award | 2022-06-03 4:25 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 8,293 | $0 | 8,293 (Direct) | View |
2022-06-01 Option Award | 2022-06-03 4:24 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | Farzan Nima Director | 8,293 | $0 | 8,293 (Direct) | View |
2022-05-11 Exercise | 2022-05-13 4:37 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0 | 151,805 (Direct) | View |
2022-05-11 Exercise | 2022-05-13 4:37 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0.3 | 151,805 (Direct) | View |
2022-04-11 Exercise | 2022-04-13 4:36 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0 | 157,105 (Direct) | View |
2022-04-11 Exercise | 2022-04-13 4:36 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0.3 | 157,105 (Direct) | View |
2022-04-06 Exercise | 2022-04-08 4:21 pm | N/A 2030-04-07 | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 1,728 | $0 | 8,002 (Direct) | View |
2022-04-06 Exercise | 2022-04-08 4:21 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 1,728 | $16 | 8,002 (Direct) | View |
2022-04-04 Exercise | 2022-04-06 4:49 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 7,950 | $0 | 162,405 (Direct) | View |
2022-04-04 Exercise | 2022-04-06 4:49 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 7,950 | $0.3 | 162,405 (Direct) | View |
2022-04-01 Exercise | 2022-04-05 4:31 pm | N/A 2030-04-07 | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 864 | $0 | 9,730 (Direct) | View |
2022-04-01 Exercise | 2022-04-05 4:31 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 864 | $16 | 9,730 (Direct) | View |
2022-03-11 Exercise | 2022-03-15 4:37 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0 | 170,355 (Direct) | View |
2022-03-11 Exercise | 2022-03-15 4:37 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0.3 | 170,355 (Direct) | View |
2022-02-11 Exercise | 2022-02-15 4:26 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0 | 173,005 (Direct) | View |
2022-02-11 Exercise | 2022-02-15 4:26 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0.3 | 173,005 (Direct) | View |
2022-02-01 Option Award | 2022-02-03 4:45 pm | N/A 2032-01-31 | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 100,000 | $0 | 100,000 (Direct) | View |
Ownership | 2022-02-03 4:37 pm | N/A 2029-09-18 | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 0 | $0 | 32,898 (Direct) | View |
2022-01-21 Option Award | 2022-01-25 4:17 pm | N/A 2032-01-20 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 165,000 | $0 | 165,000 (Direct) | View |
2022-01-21 Option Award | 2022-01-25 4:15 pm | N/A 2032-01-20 | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 50,000 | $0 | 50,000 (Direct) | View |
2022-01-21 Option Award | 2022-01-25 4:14 pm | N/A 2032-01-20 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 50,000 | $0 | 50,000 (Direct) | View |
2022-01-21 Option Award | 2022-01-25 4:12 pm | N/A 2032-01-20 | Keros Therapeutics Inc. | KROS | Cooper Simon Peter Chief Medical Officer | 50,000 | $0 | 50,000 (Direct) | View |
2022-01-11 Exercise | 2022-01-13 4:39 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0 | 175,655 (Direct) | View |
2022-01-11 Exercise | 2022-01-13 4:39 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0.3 | 175,655 (Direct) | View |
2022-01-05 Exercise | 2022-01-07 4:35 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0 | 178,305 (Direct) | View |
2022-01-05 Exercise | 2022-01-07 4:35 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 2,650 | $0.3 | 178,305 (Direct) | View |